サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1706767

アミロイドーシス治療薬市場：世界の産業分析、規模、シェア、成長、動向、2025-2035年予測

Amyloidosis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

出版日
ページ情報
英文 198 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
アミロイドーシス治療薬市場：世界の産業分析、規模、シェア、成長、動向、2025-2035年予測
出版日: 2025年02月21日
発行: Transparency Market Research
ページ情報: 英文 198 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アミロイドーシス治療薬市場- 調査範囲

TMRの調査レポート「世界のアミロイドーシス治療薬市場」は、2025年から2035年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2025年を基準年、2035年を予測年として、2019年から2035年までの世界のアミロイドーシス治療薬市場の収益と予測を提供します。また、2025年から2035年までの世界のアミロイドーシス治療薬市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、アミロイドーシス治療薬市場を推察しました。

市場スナップショット
2024年の市場規模 27億米ドル
2035年の市場規模 63億米ドル
CAGR 8.2%

当レポートでは、世界のアミロイドーシス治療薬市場の競合情勢について調査しています。世界のアミロイドーシス治療薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTが本レポートで紹介されている世界のアミロイドーシス治療薬市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー： 世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界のアミロイドーシス治療薬市場の市場分析と予測, 2020-2035年

第5章 主要洞察

  • 主要な業界イベント（パートナーシップ、コラボレーション、合併、買収など）
  • 技術的進歩
  • エンドユーザーにとっての主要な購入指標
  • ポーターのファイブフォース分析
  • PESTEL分析
  • 主要国・地域別の規制シナリオ
  • 価格動向
  • バリューチェーン分析
  • 地域別/世界別の償還シナリオ
  • 主要ブランド/製品分析

第6章 世界の市場分析と予測：薬剤のタイプ別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：タイプ別, 2020-2035年
    • モノクローナル抗体
    • プロテアソーム阻害剤
    • 免疫調節剤
    • コルチコステロイド
    • アルキル化剤
    • トランスサイレチン安定剤
    • その他
  • 医薬品のタイプ別の市場の魅力

第7章 世界の市場分析と予測：適応症別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：適応症別, 2020-2035年
    • AL（原発性）アミロイドーシス
    • AA（二次性）アミロイドーシス
    • 家族性ATTRアミロイドーシス
  • 適応症別の市場の魅力

第8章 世界の市場分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：流通チャネル別, 2020-2035年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 流通チャネル別市場の魅力

第9章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 国・地域別の市場の魅力

第10章 北米の市場分析と予測

  • 米国
  • カナダ

第11章 欧州の市場分析と予測

  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州地域

第12章 アジア太平洋地域の市場分析と予測

  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリアとニュージーランド
  • その他アジア太平洋地域

第13章 ラテンアメリカの市場分析と予測

  • ブラジル
  • メキシコ
  • その他ラテンアメリカ地域

第14章 中東・アフリカの市場分析と予測

  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

第15章 競合情勢

  • 市場企業-競合マトリックス（企業階層別・規模別）
  • 市場シェア分析企業別（2024）
  • 企業プロファイル
    • Pfizer Inc.
    • Johnson & Johnson Services, Inc.
    • GSK plc
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Alnylam Pharmaceuticals, Inc.
    • AstraZeneca
    • BridgeBio Inc.
    • Ionis Pharmaceuticals
    • Attralus, Inc.
    • Eisai Co., Ltd.
    • Other Prominent Players
図表

List of Tables

  • Table 01: Global Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Drug Type, 2020-2035
  • Table 02: Global Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020-2035
  • Table 03: Global Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 04: Global Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Region, 2020-2035
  • Table 05: North America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Country, 2020-2035
  • Table 06: North America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 07: North America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020-2035
  • Table 08: North America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 09: Europe - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Country, 2020-2035
  • Table 10: Europe - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 11: Europe - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020-2035
  • Table 12: Europe - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 13: Asia Pacific - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Country, 2020-2035
  • Table 14: Asia Pacific - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 15: Asia Pacific - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020-2035
  • Table 16: Asia Pacific - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 17: Latin America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Country, 2020-2035
  • Table 18: Latin America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 19: Latin America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020-2035
  • Table 20: Latin America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 21: Middle East & Africa - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Country, 2020-2035
  • Table 22: Middle East & Africa - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 23: Middle East & Africa - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020-2035
  • Table 24: Middle East & Africa - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035

List of Figures

  • Figure 01: Global Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Region, 2025-2035
  • Figure 02: Global Amyloidosis Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 03: Global Amyloidosis Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 04: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Monoclonal Antibodies, 2020-2035
  • Figure 05: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Proteasome Inhibitors, 2020-2035
  • Figure 06: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Immunomodulator, 2020-2035
  • Figure 07: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Corticosteroids, 2020-2035
  • Figure 08: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Alkylating Agents, 2020-2035
  • Figure 09: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Transthyretin stabilizers, 2020-2035
  • Figure 10: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Others, 2020-2035
  • Figure 11: Global Amyloidosis Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
  • Figure 12: Global Amyloidosis Therapeutics Market Attractiveness Analysis, By Indication, 2025-2035
  • Figure 13: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by AL (Primary) Amyloidosis, 2020-2035
  • Figure 14: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by AA (Secondary) Amyloidosis, 2020-2035
  • Figure 15: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Familial ATTR Amyloidosis, 2020-2035
  • Figure 16: Global Amyloidosis Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 17: Global Amyloidosis Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 18: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Hospital Pharmacies, 2020-2035
  • Figure 19: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Retail Pharmacies, 2020-2035
  • Figure 20: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Online Pharmacies, 2020-2035
  • Figure 21: Global Amyloidosis Therapeutics Market Value Share Analysis, By Region, 2024 and 2035
  • Figure 22: Global Amyloidosis Therapeutics Market Attractiveness Analysis, By Region, 2025-2035
  • Figure 23: North America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 24: North America - Amyloidosis Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 25: North America - Amyloidosis Therapeutics Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 26: North America Amyloidosis Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 27: North America Amyloidosis Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 28: North America - Amyloidosis Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
  • Figure 29: North America - Amyloidosis Therapeutics Market Attractiveness Analysis, By Indication, 2025-2035
  • Figure 30: North America - Amyloidosis Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 31: North America - Amyloidosis Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 32: Europe - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 33: Europe - Amyloidosis Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 34: Europe - Amyloidosis Therapeutics Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 35: Europe Amyloidosis Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 36: Europe Amyloidosis Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 37: Europe - Amyloidosis Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
  • Figure 38: Europe - Amyloidosis Therapeutics Market Attractiveness Analysis, By Indication, 2025-2035
  • Figure 39: Europe - Amyloidosis Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 40: Europe - Amyloidosis Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 41: Asia Pacific - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 42: Asia Pacific - Amyloidosis Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 43: Asia Pacific - Amyloidosis Therapeutics Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 44: Asia Pacific Amyloidosis Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 45: Asia Pacific Amyloidosis Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 46: Asia Pacific - Amyloidosis Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
  • Figure 47: Asia Pacific - Amyloidosis Therapeutics Market Attractiveness Analysis, By Indication, 2025-2035
  • Figure 48: Asia Pacific - Amyloidosis Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 49: Asia Pacific - Amyloidosis Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 50: Latin America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 51: Latin America - Amyloidosis Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 52: Latin America - Amyloidosis Therapeutics Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 53: Latin America Amyloidosis Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 54: Latin America Amyloidosis Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 55: Latin America - Amyloidosis Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
  • Figure 56: Latin America - Amyloidosis Therapeutics Market Attractiveness Analysis, By Indication, 2025-2035
  • Figure 57: Latin America - Amyloidosis Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 58: Latin America - Amyloidosis Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 59: Middle East & Africa - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 60: Middle East & Africa - Amyloidosis Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 61: Middle East & Africa - Amyloidosis Therapeutics Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 62: Middle East & Africa Amyloidosis Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 63: Middle East & Africa Amyloidosis Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 64: Middle East & Africa - Amyloidosis Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
  • Figure 65: Middle East & Africa - Amyloidosis Therapeutics Market Attractiveness Analysis, By Indication, 2025-2035
  • Figure 66: Middle East & Africa - Amyloidosis Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 67: Middle East & Africa - Amyloidosis Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
目次
Product Code: TMRGL86469

Amyloidosis Therapeutics Market - Scope of Report

TMR's report on the global amyloidosis therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global amyloidosis therapeutics market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global amyloidosis therapeutics market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the amyloidosis therapeutics market.

Market Snapshot
Market Value in 2024US$ 2.7 Bn
Market Value in 2035US$ 6.3 Bn
CAGR8.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global amyloidosis therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global amyloidosis therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global amyloidosis therapeutics market.

The report delves into the competitive landscape of the global amyloidosis therapeutics market. Key players operating in the global amyloidosis therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global amyloidosis therapeutics market profiled in this report.

Key Questions Answered in Global amyloidosis therapeutics Market Report:

  • What is the sales/revenue generated by amyloidosis therapeutics across all regions during the forecast period?
  • What are the opportunities in the global amyloidosis therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Amyloidosis Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global amyloidosis therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global amyloidosis therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global amyloidosis therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Amyloidosis Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Amyloidosis Therapeutics Market Analysis and Forecasts, 2020-2035
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Key Industry Events (Partnerships, Collaborations, Mergers, Acquisitions, etc.)
  • 5.2. Technological Advancements
  • 5.3. Key Purchase Metrics for End-Users
  • 5.4. PORTER's Five Forces Analysis
  • 5.5. PESTLE Analysis
  • 5.6. Regulatory Scenario by Key Countries/Regions
  • 5.7. Pricing Trends
  • 5.8. Value Chain Analysis
  • 5.9. Reimbursement Scenario by Region/globally
  • 5.10. Key Brand/Product Analysis

6. Global Amyloidosis Therapeutics Market Analysis and Forecasts, By Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Type, 2020-2035
    • 6.3.1. Monoclonal Antibodies
    • 6.3.2. Proteasome Inhibitors
    • 6.3.3. Immunomodulator
    • 6.3.4. Corticosteroids
    • 6.3.5. Alkylating Agents
    • 6.3.6. Transthyretin stabilizers
    • 6.3.7. Others
  • 6.4. Market Attractiveness By Drug Type

7. Global Amyloidosis Therapeutics Market Analysis and Forecasts, By Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Indication, 2020-2035
    • 7.3.1. AL (Primary) Amyloidosis
    • 7.3.2. AA (Secondary) Amyloidosis
    • 7.3.3. Familial ATTR Amyloidosis
  • 7.4. Market Attractiveness By Indication

8. Global Amyloidosis Therapeutics Market Analysis and Forecasts, By Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Distribution Channel, 2020-2035
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness By Distribution Channel

9. Global Amyloidosis Therapeutics Market Analysis and Forecasts, By Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast By Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness By Country/Region

10. North America Amyloidosis Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast By Drug Type, 2020-2035
    • 10.2.1. Monoclonal Antibodies
    • 10.2.2. Proteasome Inhibitors
    • 10.2.3. Immunomodulator
    • 10.2.4. Corticosteroids
    • 10.2.5. Alkylating Agents
    • 10.2.6. Transthyretin stabilizers
    • 10.2.7. Others
  • 10.3. Market Value Forecast By Indication, 2020-2035
    • 10.3.1. AL (Primary) Amyloidosis
    • 10.3.2. AA (Secondary) Amyloidosis
    • 10.3.3. Familial ATTR Amyloidosis
  • 10.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast By Country, 2020-2035
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Type
    • 10.6.2. By Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Amyloidosis Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Drug Type, 2020-2035
    • 11.2.1. Monoclonal Antibodies
    • 11.2.2. Proteasome Inhibitors
    • 11.2.3. Immunomodulator
    • 11.2.4. Corticosteroids
    • 11.2.5. Alkylating Agents
    • 11.2.6. Transthyretin stabilizers
    • 11.2.7. Others
  • 11.3. Market Value Forecast By Indication, 2020-2035
    • 11.3.1. AL (Primary) Amyloidosis
    • 11.3.2. AA (Secondary) Amyloidosis
    • 11.3.3. Familial ATTR Amyloidosis
  • 11.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 11.5.1. Germany
    • 11.5.2. UK
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Type
    • 11.6.2. By Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Amyloidosis Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Drug Type, 2020-2035
    • 12.2.1. Monoclonal Antibodies
    • 12.2.2. Proteasome Inhibitors
    • 12.2.3. Immunomodulator
    • 12.2.4. Corticosteroids
    • 12.2.5. Alkylating Agents
    • 12.2.6. Transthyretin stabilizers
    • 12.2.7. Others
  • 12.3. Market Value Forecast By Indication, 2020-2035
    • 12.3.1. AL (Primary) Amyloidosis
    • 12.3.2. AA (Secondary) Amyloidosis
    • 12.3.3. Familial ATTR Amyloidosis
  • 12.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. South Korea
    • 12.5.5. Australia & New Zealand
    • 12.5.6. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Type
    • 12.6.2. By Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Amyloidosis Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Drug Type, 2020-2035
    • 13.2.1. Monoclonal Antibodies
    • 13.2.2. Proteasome Inhibitors
    • 13.2.3. Immunomodulator
    • 13.2.4. Corticosteroids
    • 13.2.5. Alkylating Agents
    • 13.2.6. Transthyretin stabilizers
    • 13.2.7. Others
  • 13.3. Market Value Forecast By Indication, 2020-2035
    • 13.3.1. AL (Primary) Amyloidosis
    • 13.3.2. AA (Secondary) Amyloidosis
    • 13.3.3. Familial ATTR Amyloidosis
  • 13.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Type
    • 13.6.2. By Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Amyloidosis Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Drug Type, 2020-2035
    • 14.2.1. Monoclonal Antibodies
    • 14.2.2. Proteasome Inhibitors
    • 14.2.3. Immunomodulator
    • 14.2.4. Corticosteroids
    • 14.2.5. Alkylating Agents
    • 14.2.6. Transthyretin stabilizers
    • 14.2.7. Others
  • 14.3. Market Value Forecast By Indication, 2020-2035
    • 14.3.1. AL (Primary) Amyloidosis
    • 14.3.2. AA (Secondary) Amyloidosis
    • 14.3.3. Familial ATTR Amyloidosis
  • 14.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Type
    • 14.6.2. By Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2024)
  • 15.3. Company Profiles
    • 15.3.1. Pfizer Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Johnson & Johnson Services, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. GSK plc
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. Takeda Pharmaceutical Company Limited
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. Amgen Inc.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. Bristol-Myers Squibb Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. Alnylam Pharmaceuticals, Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. AstraZeneca
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. BridgeBio Inc.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments
    • 15.3.10. Ionis Pharmaceuticals
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. Business Strategies
      • 15.3.10.5. Recent Developments
    • 15.3.11. Attralus, Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Financial Overview
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. Business Strategies
      • 15.3.11.5. Recent Developments
    • 15.3.12. Eisai Co., Ltd.
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Financial Overview
      • 15.3.12.3. Financial Overview
      • 15.3.12.4. Business Strategies
      • 15.3.12.5. Recent Developments
    • 15.3.13. Other Prominent Players
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Financial Overview
      • 15.3.13.3. Financial Overview
      • 15.3.13.4. Business Strategies
      • 15.3.13.5. Recent Developments